Pacira BioSciences (PCRX) opened 2026 with Q1 revenue of US$177.4 million and basic EPS of US$0.07, while trailing twelve month figures sit at US$734.9 million of revenue and basic EPS of US$0.12 as the company remains in positive net income territory. Over recent quarters, revenue has moved between US$168.9 million and US$196.9 million with basic EPS ranging from a loss of US$0.11 to a high of US$0.35, providing a clear view of how profitability has been stabilising around modest net income. With that backdrop, investors are likely to focus on how much of this quarter’s earnings quality reflects cleaner underlying margins versus prior periods that were shaped by one off items.

See our full analysis for Pacira BioSciences.

With the headline numbers on the table, the next step is to see how they compare with the most common narratives around Pacira BioSciences's growth, risks, and profitability to test which storylines still hold up and which may need a rethink.

Profitability steadies around small net income

• Q1 2026 net income excluding extra items was US$2.9 million on US$177.4 million of revenue, compared with quarterly net income figures over the last year that ranged from a loss of US$4.8 million to a profit of US$16.0 million.
• Bulls point to this return to profitability, with trailing twelve month net income of US$5.1 million, as supporting their view that Pacira can grow earnings quickly. However, the data also show that earnings over the past five years declined by 55.6% per year, which means:
  • The bullish case for higher future margins sits against a history where profitability has moved between quarterly profits and losses, including the Q2 2025 loss of US$4.8 million despite revenue of US$181.1 million.
  • Forecast earnings growth of about 25.8% a year is being built on a relatively small current profit base. As a result, even modest swings in quarterly net income, like the shift from US$16.0 million in Q4 2024 to US$2.9 million in Q1 2026, can have a big impact on those growth percentages.

Pacira's latest profit figure gives bulls something concrete to point to. At the same time, the swings between losses and double digit million profits over recent quarters are exactly what those bullish forecasts need to smooth out over time to play out as expected. 🐂 Pacira BioSciences Bull Case

One off loss and past declines still matter

• Over the last twelve months Pacira recorded total revenue of US$734.9 million and net income excluding extra items of US$5.1 million, and that period also includes a one off loss of US$10.9 million alongside a five year earnings decline of 55.6% per year.
• Bears argue that this history of earnings decline and the presence of large one time items undercut the quality of recent profits, and the trailing figures give that view some support:
  • Trailing twelve month basic EPS moved from a loss of US$2.15 in Q4 2024 to a small profit of US$0.12 by Q1 2026. This is a very large swing that partly reflects one off adjustments rather than a long record of steady profit.
  • The Q2 2025 trailing twelve month net loss of US$127.5 million still sits within the comparison period, so the recent small annual profit of US$5.1 million is being measured against a year that includes a very large loss and a separate US$10.9 million one off item.

For a cautious investor, it is worth treating the recent move into profitability as a starting point and not assuming that historical swings in earnings and one off charges have fully washed out of the numbers yet. 🐻 Pacira BioSciences Bear Case

Low P/S and high DCF fair value gap

• With a current share price of US$24.44 and a price to sales ratio of 1.3x compared with peer and industry averages of 3.7x and 5.2x, Pacira is being compared with a DCF fair value of about US$511.29, while the consensus analyst price target sits much closer at US$29.00.
• Consensus narrative suggests this set up reflects a company that has just turned profitable with moderate forecast revenue growth of 6.1% per year, and the numbers show why views differ:
  • The wide gap between the US$24.44 share price and the DCF fair value of about US$511.29 is far larger than the difference between the share price and the US$29.00 analyst target. This implies that valuation depends heavily on which model or assumptions investors focus on.
  • At the same time, revenue over the last four reported quarters has moved within a relatively tight band from US$168.9 million to US$196.9 million, so anyone relying on aggressive top line assumptions needs to reconcile that with the more modest 6.1% annual revenue growth forecast in the data.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Pacira BioSciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With such a mixed picture across profits, one off items and valuation signals, it helps to get closer to the source data and stress test what matters most to you. If you want a clearer sense of where the balance sits, start by weighing up the 4 key rewards and 1 important warning sign.

See What Else Is Out There

Pacira's earnings story still carries weaknesses, with modest trailing profits, past annual losses and one off items making the recent profitability look fragile.

If you want stocks where recent profits look more consistent and less dependent on special charges, start comparing alternatives in the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.